Active Ingredient(s): Dalbavancin Hydrochloride
FDA Approved: * May 23, 2014
Category: Antibiotics

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Dalvance Overview

Dalbavancin (INN, trade names Dalvance in the US and Xydalba in the EU) is a novel second-generation lipoglycopeptide antibiotic medication. It belongs to the same class as vancomycin, the most widely used and one of the few treatments available to patients infected with methicillin-resistant Staphylococcus aureus (MRSA).[2] Dalbavancin is a semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available, vancomycin and teicoplani...

Read more Dalvance Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dalbavancin

Recent Dalvance Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Dalbavancin Hydrochloride
  • Injection: 500mg/vial
  • Powder: 500mg/vial
  • Powder, Lyophilized: 500mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Dalvance: (1 result)

Sorted by National Drug Code
  • 57970-100 Dalvance 500 mg/25ml Intravenous Injection, Powder, for Solution by Durata Therapeutics Inc.

Other drugs which contain Dalbavancin Hydrochloride or a similar ingredient: (1 result)